论文部分内容阅读
目的:探讨使用腹腔化疗治疗晚期消化系统肿瘤合并腹腔积液的临床疗效。方法:选取我院2010年3月至2014年3月收治的晚期消化系统肿瘤患者21例作为研究对象,对其临床资料进行回顾性分析。所选患者均使用腹腔化疗,现探讨其治疗效果及毒副反应。结果:21例患者接受腹腔化疗后PR率为33.33%,19.05%患者出现一过性腹痛、恶心、呕吐、食欲不振等,给予对症处理后缓解,患者未见明显的肝肾功能损害与骨髓抑制现象。结论:对晚期消化道肿瘤患者使用腹腔化疗有较高PR率,可增强腹腔药物浓度,延长药物与癌细胞接触时间,且安全可靠,不良反应较少且轻微,可对患者生活质量予以显著改善,有临床推广价值。
Objective: To investigate the clinical efficacy of intraperitoneal chemotherapy in the treatment of advanced digestive system tumors combined with ascites. Methods: Twenty-one patients with advanced digestive system tumors admitted to our hospital from March 2010 to March 2014 were selected as the research object, and their clinical data were retrospectively analyzed. The selected patients were treated with intraperitoneal chemotherapy, is to explore the therapeutic effect and toxicity. Results: The PR rate of 21 patients after receiving intraperitoneal chemotherapy was 33.33%. 19.05% patients had transient abdominal pain, nausea, vomiting and loss of appetite. After symptomatic treatment was relieved, patients had no obvious liver-kidney dysfunction and bone marrow suppression phenomenon. Conclusion: The higher PR rate in patients with advanced gastrointestinal cancer treated with intraperitoneal chemotherapy can enhance the intraperitoneal drug concentration, extend the contact time of drug and cancer cells, and safe and reliable, with fewer and minor adverse reactions, and can significantly improve the quality of life of patients , A clinical promotion of value.